NYSE:EVHC - Envision Healthcare Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$44.15 +0.07 (+0.16 %)
(As of 07/19/2018 04:00 PM ET)
Previous Close$44.08
Today's Range$43.75 - $44.42
52-Week Range$23.77 - $63.31
Volume2.09 million shs
Average Volume3.44 million shs
Market Capitalization$5.43 billion
P/E Ratio17.85
Dividend YieldN/A
Beta0.45
Envision Healthcare logoEnvision Healthcare Corporation, through its subsidiaries, provides various healthcare services in the United States. The company operates through two segments, Physician Services and Ambulatory Services. As of December 31, 2017, its physician-led services encompassed providers at approximately 1,800 clinical departments at healthcare facilities in 45 states and the District of Columbia that include emergency department and hospitalist, anesthesiology, radiology/tele-radiology, and children's services. The company also offers ambulatory surgical centers (ASCs) services that provide surgical procedures across multiple specialties, including gastroenterology, ophthalmology, orthopedics, and others. It operated 264 ASCs in 35 states and the District of Columbia. In addition, it provides surgery services, such as management, oversight, and surgeon staffing for trauma surgery services; offers direct patient care and care coordination by clinicians outside the acute care setting through physician-led post-acute care services; and operates office-based medical practices that primarily focus on women's health, as well as provides physician staffing and related management services. Further, it offers medical transportation services in 41 states and the District of Columbia. The company offers its clinical solutions for health systems, payors, providers, and patients. Envision Healthcare Corporation was founded in 1992 and is based in Nashville, Tennessee.

Receive EVHC News and Ratings via Email

Sign-up to receive the latest news and ratings for EVHC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Offices & clinics of medical doctors
Sub-IndustryN/A
SectorMedical
SymbolNYSE:EVHC
CUSIPN/A
Phone615-665-1283

Debt

Debt-to-Equity Ratio0.65
Current Ratio2.27
Quick Ratio2.25

Price-To-Earnings

Trailing P/E Ratio17.85
Forward P/E Ratio12.95
P/E Growth1.1

Sales & Book Value

Annual Sales$12.18 billion
Price / Sales0.44
Cash Flow$6.1065 per share
Price / Cash7.23
Book Value$59.24 per share
Price / Book0.75

Profitability

EPS (Most Recent Fiscal Year)$2.48
Net Income$-228,000,000.00
Net Margins1.41%
Return on Equity4.59%
Return on Assets1.97%

Miscellaneous

Employees69,300
Outstanding Shares121,130,000
Market Cap$5,432.59

Envision Healthcare (NYSE:EVHC) Frequently Asked Questions

What is Envision Healthcare's stock symbol?

Envision Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVHC."

How will Envision Healthcare's stock buyback program work?

Envision Healthcare declared that its board has initiated a share buyback program on Tuesday, September 19th 2017, which permits the company to buyback $250,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 4.5% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's board believes its shares are undervalued.

How were Envision Healthcare's earnings last quarter?

Envision Healthcare (NYSE:EVHC) posted its earnings results on Monday, May, 7th. The company reported $0.71 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.64 by $0.07. The firm earned $2.08 billion during the quarter, compared to analysts' expectations of $2.02 billion. Envision Healthcare had a net margin of 1.41% and a return on equity of 4.59%. Envision Healthcare's quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.77 EPS. View Envision Healthcare's Earnings History.

When is Envision Healthcare's next earnings date?

Envision Healthcare is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Envision Healthcare.

What guidance has Envision Healthcare issued on next quarter's earnings?

Envision Healthcare issued an update on its FY18 earnings guidance on Monday, May, 7th. The company provided earnings per share guidance of $3.49-3.70 for the period, compared to the Thomson Reuters consensus estimate of $3.59. The company issued revenue guidance of $8.35-8.53 billion, compared to the consensus revenue estimate of $8.41 billion.Envision Healthcare also updated its Q2 guidance to $0.83-0.90 EPS.

What price target have analysts set for EVHC?

16 brokers have issued twelve-month target prices for Envision Healthcare's shares. Their predictions range from $31.00 to $51.00. On average, they anticipate Envision Healthcare's share price to reach $41.30 in the next year. This suggests that the stock has a possible downside of 6.5%. View Analyst Ratings for Envision Healthcare.

What is the consensus analysts' recommendation for Envision Healthcare?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Envision Healthcare in the last year. There are currently 12 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

What are Wall Street analysts saying about Envision Healthcare stock?

Here are some recent quotes from research analysts about Envision Healthcare stock:
  • 1. According to Zacks Investment Research, "Envision Healthcare’s shares have outperformed the industry’s gain year to date. Given its strong fundamentals, the shares of the company are expected to continue the bull run in the upcoming quarters. It has witnessed its 2018 and 2019 estimates move upward over the past 90 days.  The company’s impressive revenue growth was driven by the company’s Physicians Services segment. It is optimistic about the physician services market, witnessing consolidation. Also, the divestiture of its AMR business will help the company focus on its core operations. The company’s strategic acquisitions to bring inorganic growth has also been a driving force. However, the company suffers high leverage, leading to increased interest ratio. Its operating expense is exceeding the revenue growth and exerting pressure on the operating margins." (7/10/2018)
  • 2. Canaccord Genuity analysts commented, "We reiterate our BUY rating and raise our PT to $46 based on an improving financial outlook given restructuring and easing utilization headwinds. The company characterized guidance as highly visible and not heroic. As such, we recommend continued exposure as utilization headwinds dissipate and the operational improvement plan takes hold. Key positive: High visibility into 2018 guidance: The low-end of 2018 adj-EBITDA of $960M is 87% in hand when annualizing 4Q’17. M&A from 2017 and 2018 should contribute an incremental $10-$15M and $20-$30M, respectively, bringing visibility up to 92% coverage at the low-end. Organic growth and further expense benefits from operational improvements would be the last leg in getting to guidance. Key negative: Consolidated organic growth rate lowered to 2-5% (was 3-6%) taking into account a softer utilization environment." (2/28/2018)
  • 3. Cantor Fitzgerald analysts commented, "Revised 2018 estimates. We are lowering our 2018 adjusted EPS estimate to $3.75 from $3.95 and bringing down our adjusted 2018 EBITDA estimate to $950.6 million from $982 million to account for slightly higher seasonality, primarily in terms of salary, wages and benefits, which account for the majority of EVHC’s operating expenses. Our new estimate is just below the $960 million midpoint of management’s potential 2018 performance, as outlined in a presentation last November, but it remains above the $925.1 million FactSet consensus." (2/21/2018)

Who are some of Envision Healthcare's key competitors?

Who are Envision Healthcare's key executives?

Envision Healthcare's management team includes the folowing people:
  • Mr. Christopher A. Holden, CEO, Pres & Director (Age 54)
  • Ms. Claire M. Gulmi, Advisor (Age 64)
  • Mr. Kevin D. Eastridge, Exec. VP & CFO (Age 53)
  • Mr. Karey Lynn Witty, Exec. VP & COO (Age 53)
  • Mr. Kenneth E Zongor, Sr. VP & Chief Accounting Officer (Age 42)

Has Envision Healthcare been receiving favorable news coverage?

Headlines about EVHC stock have trended somewhat negative this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Envision Healthcare earned a coverage optimism score of -0.06 on Accern's scale. They also gave news coverage about the company an impact score of 47.74 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Envision Healthcare's major shareholders?

Envision Healthcare's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Tokio Marine Asset Management Co. Ltd. (0.11%), Bank of Montreal Can (0.08%), Havens Advisors LLC (0.06%), State of Alaska Department of Revenue (0.02%), Thompson Investment Management Inc. (0.02%) and Livforsakringsbolaget Skandia Omsesidigt (0.01%). Company insiders that own Envision Healthcare stock include John Thomas Gawaluck and Robert Jon Coward. View Institutional Ownership Trends for Envision Healthcare.

Which major investors are selling Envision Healthcare stock?

EVHC stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Bank of Montreal Can, Sit Investment Associates Inc., Exane Derivatives, Hartford Investment Management Co., Municipal Employees Retirement System of Michigan and Thompson Investment Management Inc.. View Insider Buying and Selling for Envision Healthcare.

Which major investors are buying Envision Healthcare stock?

EVHC stock was acquired by a variety of institutional investors in the last quarter, including Tokio Marine Asset Management Co. Ltd., Havens Advisors LLC, Livforsakringsbolaget Skandia Omsesidigt, Sphinx Trading LP, XR Securities LLC, Contravisory Investment Management Inc., Oakbrook Investments LLC and State of Alaska Department of Revenue. View Insider Buying and Selling for Envision Healthcare.

How do I buy shares of Envision Healthcare?

Shares of EVHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Envision Healthcare's stock price today?

One share of EVHC stock can currently be purchased for approximately $44.15.

How big of a company is Envision Healthcare?

Envision Healthcare has a market capitalization of $5.43 billion and generates $12.18 billion in revenue each year. The company earns $-228,000,000.00 in net income (profit) each year or $2.48 on an earnings per share basis. Envision Healthcare employs 69,300 workers across the globe.

How can I contact Envision Healthcare?

Envision Healthcare's mailing address is 1A BURTON HILLS BOULEVARD, NASHVILLE TN, 37215. The company can be reached via phone at 615-665-1283 or via email at [email protected]


MarketBeat Community Rating for Envision Healthcare (NYSE EVHC)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  488 (Vote Outperform)
Underperform Votes:  269 (Vote Underperform)
Total Votes:  757
MarketBeat's community ratings are surveys of what our community members think about Envision Healthcare and other stocks. Vote "Outperform" if you believe EVHC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVHC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.